TIGER'S TAKE: On our watch list/trading list. Has had a good year so far. Potential is very high for what looks to be a 'blockbuster' drug. $AMRNAmarin analyst commentary at Cantor FitzgeraldAmarin equity raise could accelerate Vascepa growth, says Cantor Fitzgerald. Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on Amarin post the company's recent equity raise. The proceeds should help accelerate the growth of Vascepa, which could have peak sales of $5B-$10B, Chen tells investors in a research note. FactSet forecasts are $2.1B of sales by 2024, the analyst points out in a note titled "AMRN Is Just Running Up That Hill; Peak Sales Could Exceed Great Expectations."Source: (thefly.com) $AMRN, Amarin Corporation plc / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page.